Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T18:07:17.325Z.
Calculation as of: 2026-10-06T18:07:17.325Z.
Quote observation: 2026-10-06T18:05:03.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: df0d51bc4c7c4fe031789de0e9442acf829cec50a05ec95901a80cda74a8a9f3
PE RATIO
N/A
Market Cap
$3.03B
PE Ratio
116.00
TTM Avg
121.55
3Y Avg
121.55
5Y Avg
121.55
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | $2.99B | N/A | N/A | N/A | N/A |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $3.03B | 116.00 | 121.55 | 121.55 | 121.55 |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.08B | N/A | 7.81 | 7.81 | 7.81 |
| Denali Therapeutics Inc. (DNLI)vs › | $3.10B | N/A | 239.54 | 239.54 | 239.54 |
| Dyne Therapeutics, Inc. (DYN)vs › | $2.84B | N/A | N/A | N/A | N/A |
| TransMedics Group, Inc. (TMDX)vs › | $2.80B | 20.99 | 33.77 | 471.31 | 471.31 |
| AtriCure, Inc. (ATRC)vs › | $2.79B | 258.39 | 234.61 | 234.61 | 81.83 |
| Tarsus Pharmaceuticals, Inc. (TARS)vs › | $3.19B | N/A | N/A | N/A | N/A |
| Precigen, Inc. (PGEN)vs › | $2.71B | N/A | 14.11 | 14.11 | 14.11 |
| Acadia Healthcare Company, Inc. (ACHC)vs › | $2.67B | N/A | 12.43 | 16.75 | 20.41 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$41.84
Forward EPS (Est.)
$-1.84
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
